Intrinsic Imaging and Merge Healthcare Announce Technology Agreement - Intrinsic to be First to Implement Industry Changing Imaging Technology

Share Article

Intrinsic’s team of more than sixty board-certified diagnostic radiologists will utilize Merge CIMS for complete clinical trial image management. The coupling of Intrinsics deep radiology, therapeutic and clinical trial expertise with Merge's advanced imaging technologies will revolutionize how imaging in clinical trials is currently performed and evaluated.

"The coupling of our deep radiology, therapeutic and clinical trial expertise with advanced imaging technologies will revolutionize how imaging in clinical trials is currently performed and evaluated." says Todd A. Joron, President and COO of Intrinsic

Intrinsic Imaging LLC, a bio/pharmaceutical medical imaging services organization and Merge Healthcare (NASDAQ: MRGE), a market leader in health IT solutions, announce today that they have entered into a technology agreement and Intrinsic will become the first company to implement Merge’s new Clinical Imaging Management System (CIMS).

Merge CIMS™ is the first commercially available solution for managing all aspects of imaging in clinical trials. Through defining investigator sites, enabling rapid electronic image acquisition from these sites over the Internet, providing detailed image tracking and enabling the rapid radiologic analysis, adjudication and reporting of images, CIMS enables the transparent execution of imaging trials complete with seamless EDC integration.

“At Intrinsic we are leading the redefinition of how medical imaging services are provided within clinical trials. This will result in Intrinsic performing medical imaging trials more efficiently and cost effectively than other service providers.” says Todd A. Joron, President and COO of Intrinsic. “The coupling of our deep radiology, therapeutic and clinical trial expertise with advanced imaging technologies will revolutionize how imaging in clinical trials is currently performed and evaluated.”

Intrinsic’s team of more than sixty board-certified diagnostic radiologists will utilize Merge CIMS for complete clinical trial image management. Intrinsic’s experienced clinical team provides pharmaceutical and biotech sponsors with comprehensive imaging core lab services across all therapeutic areas including oncology, neurology, cardiology, rheumatology, and endocrinology.

“Intrinsic’s team is recognized in the industry as having extensive clinical trial and technology expertise and we are delighted to have them as a partner for our new clinical imaging solution” says Justin Dearborn, Merge CEO. “We are excited about the impact our CIMS solution will have in helping Intrinsic drive productivity and efficiency throughout the entire imaging workflow within a clinical trial.”

About Merge Healthcare
Merge Healthcare (NASDAQ: MRGE) develops and integrates information technology to create a better electronic healthcare experience. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years. Additional information can be found at http://www.merge.com.

About Intrinsic Imaging LLC
Located in San Antonio, Texas, Intrinsic is a bio/pharmaceutical services organization providing complete image management and radiological review services to global pharmaceutical, biotechnology and medical device organizations. With its team of more than sixty sub-specialized, board-certified radiologists, and through its use of advanced medical imaging technology, Intrinsic’s experienced clinical trial team provides pharmaceutical and biotech sponsors with comprehensive imaging core lab services across all therapeutic areas. For more information, please visit http://www.IntrinsicCRO.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Todd Joron

Julie Pekarek
Visit website